Targeted therapies for hepatocellular carcinoma

Jonas W. Feilchenfeldt, Eileen M. O'Reilly, Costantine Albany, Ghassan K. Abou-Alfa

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The liver's role in xenobiotic metabolism, i.e., the modification of drugs and toxic foreign compounds, has long served as a putated explanation for inherent drug resistance of hepatocellular carcinoma (HCC). Therefore, it does not come as a surprise that the initial discovery of the multiple-drug resistance gene (MDR) was in liver tissue [1], and hepatocyte cell lines are a natural reservoir for the study of drug resistance.

Original languageEnglish (US)
Title of host publicationHepatocellular Carcinoma
Subtitle of host publicationTargeted Therapy and Multidisciplinary Care
PublisherSpringer New York
Pages355-368
Number of pages14
ISBN (Print)9781603275217
DOIs
StatePublished - Dec 1 2011

Keywords

  • Bevacizumab
  • Erlotinib
  • HCC etiology
  • HCC targeted therapies
  • Sorafenib
  • Sunitinib
  • Tyrosine kinase inhibitors (TKIs)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Targeted therapies for hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Feilchenfeldt, J. W., O'Reilly, E. M., Albany, C., & Abou-Alfa, G. K. (2011). Targeted therapies for hepatocellular carcinoma. In Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary Care (pp. 355-368). Springer New York. https://doi.org/10.1007/978-1-60327-522-4_22